A Study of the Safety and Efficacy of Synvisc and Depo-Medrol in Patients With Osteoarthritis of the Hip

Phase 3

Completed

• Conditions: Osteoarthritis, Hip; Musculoskeletal Diseases

• Registration Number: NCT00131326
• Lead Sponsor: Genzyme, a Sanofi Company

Brief Summary

This is a clinical study to investigate the safety and efficacy of Synvisc and Depo-Medrol in treating patients with osteoarthritis (OA) of the hip.

Detailed Description

Not available

Study Timeline

• Study Start: 2003-11
• Study First Submitted: 2005-08-17
• Study First Submitted QC: 2005-08-17
• Study First Posted: 2005-08-18
• Study Completion: 2006-04
• Status Verified: 2017-07
• Last Update Submitted: 2017-07-27
• Last Update Posted: 2017-07-31

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• Patients with symptomatic osteoarthritis pain of hip

Exclusion Criteria

• Patients with current or prior conditions or treatment that would impede measurement of efficacy and safety

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Pain relief

Trial Locations

Locations (32)

Alabama Clinical Therapeutics; 🇺🇸 Birmingham, Alabama, United States

John Higginbotham, MD Sports Medicine; 🇺🇸 Huntsville, Alabama, United States

Affiliated Orthopedic Specialists; 🇺🇸 Scottsdale, Arizona, United States

Arkansas Orthopaedic Specialists; 🇺🇸 Little Rock, Arkansas, United States

Cedars-Sinai Orthopedic Center; 🇺🇸 Los Angeles, California, United States

Jackson Arthritis Center; 🇺🇸 Oakland, California, United States

Orthopedic Medical Group; 🇺🇸 San Diego, California, United States

Orthopedic Specialists of Tamp Bay, P.A.; 🇺🇸 Clearwater, Florida, United States

Orthopedic Institute at Mercy Hospital; 🇺🇸 Miami, Florida, United States

Hughston Sports Medicine Foundation; 🇺🇸 Columbus, Georgia, United States

Scroll for more (22 remaining)